12:00 AM
 | 
Jun 22, 2009
 |  BioCentury  |  Emerging Company Profile

Beactica: More Efficient Resonance

Surface plasmon resonance, or SPR, is used in fragment-based drug discovery because it provides a wealth of information about how a compound or fragment interacts with its target. Beactica AB is seeking to improve the interpretation of that information, and subsequently the optimization of leads, with an add-on to GE Healthcare's Biacore SPR discovery platform.

The newco initially will perform contract research to generate revenues it can use to advance its own pipeline of small molecules.

Biacore provides information about how compounds and their targets interact in real time, including how quickly they bind, how long they remain bound, and how quickly they dissociate. The platform...

Read the full 511 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >